Close Menu

NEW YORK (GenomeWeb) – Precipio is out of compliance with a Nasdaq listing requirement, the firm said in a document filed Friday with the US Securities and Exchange Commission.

The company said Nasdaq notified it on March 26 that for the past 30 consecutive business days, the closing bid price per share of its common stock was below the $1 minimum needed for continued listing.

Nasdaq has given Precipio a grace period until Sept. 24, 2018 to regain compliance by ensuring that its common stock price meets or exceeds $1 per share for at least 10 consecutive business days.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.